British Virgin Islands-based biotechnology firm Juvenescence Ltd. has finalized the first phase of its Series B funding round.
Juvenescence has secured $46 million at $24.70 per share and the company intends to secure between $100 million to $125 million in total.
The price of the Series B round values the company at $400 million, a 58 percent premium to the price at which Guernsey-based closed-ended investment company FastForward infused in Juvenescence’s Series A funding last year.
Juvenescence has raised a total of $62.3 million in over 2 funding rounds.